1234563-16-6

1234563-16-6 structure

Name: Epetraborole hydrochloride
Chemical Name: (3S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-2,1-benzoxaborol-1(3H)-ol hydrochloride (1:1)
CAS Number: 1234563-16-6
Molecular Formula: C₁₁H₁₇BClNO₄
Molecular Weight: 273.521
Catalog: Research Areas Infection
Create Date: 2018-03-11 13:02:48
Modify Date: 2024-01-13 14:14:24
Epetraborole hydrochloride is a novel leucyl-tRNA synthetase (LeuRS) inhibitor, which inhibits protein synthesis by binding "to the terminal adenosine ribose (A76) of leucyl-tRNA synthetase". It is intended for the treatment of infections caused by Gram-negative bacteria. Epetraborole hydrochloride is a bacteriostatic compound that can against a wide range of anaerobic and Gram-negative bacteria, including multidrug-resistant pathogens, such as extended-spectrum-β-lactamase-, metallo-β-lactamase-, and carbapenemase-producing organism.

Name	(3S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-2,1-benzoxaborol-1(3H)-ol hydrochloride (1:1)
Synonyms	(3S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-2,1-benzoxaborol-1(3H)-ol hydrochloride (1:1) 1-Propanol, 3-[[(3S)-3-(aminomethyl)-1,3-dihydro-1-hydroxy-2,1-benzoxaborol-7-yl]oxy]-, hydrochloride (1:1) Epetraborole HCl Epetraborole hydrochloride AN3365 Epetraborole (hydrochloride)

Description	Epetraborole hydrochloride is a novel leucyl-tRNA synthetase (LeuRS) inhibitor, which inhibits protein synthesis by binding "to the terminal adenosine ribose (A76) of leucyl-tRNA synthetase". It is intended for the treatment of infections caused by Gram-negative bacteria. Epetraborole hydrochloride is a bacteriostatic compound that can against a wide range of anaerobic and Gram-negative bacteria, including multidrug-resistant pathogens, such as extended-spectrum-β-lactamase-, metallo-β-lactamase-, and carbapenemase-producing organism.
Related Catalog	Signaling Pathways >> Others >> Others Research Areas >> Infection
References	[1]. Goldstein EJ et al. Comparative in vitro activities of GSK2251052, a novel boron-containing leucyl-tRNA synthetase inhibitor, against 916 anaerobic organisms.Antimicrob Agents Chemother. 2013 May;57(5):2401-4. [2]. O'Dwyer K et al. Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment ofcomplicated urinary tract infections. Antimicrob Agents Chemother. 2015 Jan;59(1):289-98.